Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

ease of $21.3 million, or 10.3%, over the prior year quarter. The primary drivers of the increase in revenue, as compared to the prior year quarter, were the net sales of two products, LOESTRIN 24 FE and TACLONEX.

Sales of our oral contraceptive products increased $8.4 million, or 13.9%, in the quarter ended December 31, 2007, compared with the prior year quarter. LOESTRIN 24 FE generated revenues of $41.6 million in the quarter ended December 31, 2007, compared to $21.5 million in the prior year quarter. The increase in revenues was primarily due to an increase of 93.8% in filled prescriptions for LOESTRIN 24 FE compared to the prior year quarter. Filled prescriptions of LOESTRIN 24 FE increased 6.5% sequentially in the quarter ended December 31, 2007, compared to the quarter ended September 30, 2007. We introduced and began commercial sales of FEMCON FE in the second half of 2006, but did not initiate promotional efforts in support of the product until April 2007. Beginning in April 2007, FEMCON FE became a promotional priority for our Chilcott sales force and generated revenues of $11.6 million in the quarter ended December 31, 2007, an increase of $4.1 million, or 53.3%, versus the prior year quarter. The increase in revenues was primarily due to a 200.0% increase in filled prescriptions for FEMCON FE compared to the prior year quarter. Filled prescriptions of FEMCON FE increased 15.0% sequentially in the quarter ended December 31, 2007 compared to the quarter ended September 30, 2007. Net sales of ESTROSTEP FE decreased $13.9 million, or 58.0%, in the quarter ended December 31, 2007 compared to the prior year quarter. The decrease in revenues was due to the introduction of generic versions of ESTROSTEP FE beginning in late October 2007, which lowered filled prescriptions of ESTROSTEP FE by 60.6% versus the prior year quarter. At the time of the launch of a generic version of ESTROSTEP FE, we partnered with Watson Pharma, Inc. to launch Tilia(TM) Fe, an a
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... , Not for release, publication or distribution (in ... where to do so would constitute a violation of the ... or the "Company") (LSE: SHP, NASDAQ: SHPG ) ... held a meeting with representatives of AbbVie. This ... or approval of AbbVie. A further update will ...
(Date:7/11/2014)... Research and Markets  has announced the addition of ... Analysis, Size, Share, Growth, Trends and Forecast to 2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is a technique ... into cells. This technology helps the cells to regulate ... by affecting the nuclear genes. The transfection technology market ...
(Date:7/11/2014)... July 11, 2014 BCC Research ( ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , ... technology reached nearly $140 billion in 2013. This is ... a five-year compound annual growth rate (CAGR) of 28.6%. ... of interesting and exciting possibilities within the broader PCR ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3
... Nov. 20 Amicus Therapeutics,(Nasdaq: FOLD ) today ... will present a corporate update at the Lazard Capital,Markets ... Tuesday,November 27th at 11:30 am ET at The New ... of the presentation will be available to all,interested parties ...
... Massachusetts and RAMBOUILLET, France,November 20 ... model-based,vision software for musculoskeletal radiography, and ... High Resolution Digital Radiology for osteoarticular,imaging, ... joint and bone,tissues, announced today the ...
... Completion of Strategic Acquisition Reflected in Q3 Results, ... Board: ECTE) today announced financial results for the,third quarter ... 30,2007, net loss was $8,677,000 or $.70 per share, ... period in 2006. For the nine months ended,September 30, ...
Cached Biology Technology:Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 3Rapid Quantification of Osteoarthritis With a Novel, Office-Based, High-Resolution Digital Imaging Device 2Echo Therapeutics Reports Third Quarter 2007 Results 2Echo Therapeutics Reports Third Quarter 2007 Results 3Echo Therapeutics Reports Third Quarter 2007 Results 4Echo Therapeutics Reports Third Quarter 2007 Results 5Echo Therapeutics Reports Third Quarter 2007 Results 6
(Date:7/11/2014)... Wildlife Conservation Society shows that no-take zones in ... such as lobster, conch, and fish recover from ... areas. , The reporttitled "Review of the Benefits ... literature from no-take areas around the world. The ... recognized expert in marine protected areas and fisheries ...
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... burning in eastern New South Wales, Australia when NASA,s ... 03:35 UTC on July 11 (12:35 p.m. local time/11:35 ... eastern New South Wales (NSW), the Moderate Resolution Imaging ... the region and spotted smoke (light brown) from various ... are outlined in red. , The New South Wales, ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... release is available in Spanish . , ... processes, but also those that do not. This is why ... healthy cells. With this aim in mind, a team from ... of the C1P molecule. Today two types of ...
... N.Y. New tires allow race cars to take tight ... similar advantages: They are not necessary for basic flight but ... "To escape a predator, you don,t have to be fast, ... a world authority on animal behavior, ecology and evolution and ...
... pollution has already spurred public health officials to advise eating ... in a warmer world. So suggests a paper that ... . Sue Natali, a postdoctoral associate in botany at ... mercury levels in soils under trees growing in air enriched ...
Cached Biology News:The quest for specific anti-inflammatory treatment 2The quest for specific anti-inflammatory treatment 3Hind wings help butterflies make swift turns to evade predators, study finds 2To climate-change worries, add 1 more: Extended mercury threat 2To climate-change worries, add 1 more: Extended mercury threat 3
...
These 25x25 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 102...
... Magnetic Bead Separation is a powerful ... clinical applications. Typical applications are DNA/RNA or ... ,This has been fully automated on ... magnetic separator Te-MagS. ,In combination with ...
... Collection of Cell Cultures (ECACC) has been ... academia and government institutes for over seven ... designed to introduce candidates to cell culture ... on more specialist areas such as planning ...
Biology Products: